

NOVO NORDISK A S
Form 6-K
January 02, 2014

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

January 2, 2014

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

**Novo Allé
DK- 2880, Bagsvaerd
Denmark**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Status regarding Novo Nordisk's holding of its own shares (31 December 2013)

Bagsværd, Denmark, 2 January 2014 – In continuation of the company's announcements dated 31 January 2013 and 31 October 2013 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2013 owned 102,852,025 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 20,570,405 or 3.7% of the total share capital.

In the fourth quarter of 2013 a total of 15,327,405 B shares of DKK 0.20 were repurchased, and 1,940,620 B shares of DKK 0.20 were disposed of to employees in connection with employee incentive programmes.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com
Frank Daniel Mersebach +45 3079 0604 fdni@novonordisk.com
Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Jannick Lindegaard (US) +1 609 235 8567 jlis@novonordisk.com

Novo Nordisk A/S Novo Allé Telephone: Internet:
Investor Relations 2880 +45 4444 8888 www.novonordisk.com
Bagsværd
Denmark CVR no:

Edgar Filing: NOVO NORDISK A S - Form 6-K

24 25 67 90

Company announcement No 1 / 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: January 2, 2014 Lars Rebien Sørensen,

President and Chief Executive Officer